--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--
--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS$(R)$ revenue from existing indications--
--Preparation remains on track for SIR meeting with FDA regarding the IGE PMA supplement, supported by 24-month NAUTILUS data showing a 100% median reduction in GTC seizures among evaluable patients(1) --
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--August 11, 2026--
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Second Quarter 2026 Financial Highlights
-- Total revenue of $22.8 million in the second quarter of 2026
-- RNS System revenue of $22.5 million in the quarter, representing 21.3%
growth compared to the second quarter of 2025
-- Net loss in the second quarter of 2026 was ($6.2) million compared to
($10.0) million in the second quarter of 2025
-- Adjusted EBITDA loss of ($2.8) million for the second quarter of 2026,
an improvement of $2.1 million compared to a loss of ($4.9) million in
the second quarter of 2025
Second Quarter 2026 Operational & Strategic Highlights
-- Launched ECoG Assistant$(TM)$, the first in a planned suite of NeuroPace AI-based clinical decision support tools, uniquely enabled by NeuroPace's proprietary long-term intracranial EEG dataset and designed to help physicians more efficiently review ECoG data and inform individualized treatment decisions -- Published 18-month NAUTILUS results in Epilepsia, a leading peer-reviewed epilepsy journal, providing Level 1 evidence from the first randomized controlled neuromodulation trial in drug-resistant IGE and demonstrating a 77% median reduction in GTC seizures. -- Reached new all-time highs in active prescribers, accounts and patient pipeline
"Second-quarter performance showed continued momentum in our core RNS business driven by increased adoption within our current focal epilepsy indication," said Joel Becker, Chief Executive Officer of NeuroPace. "We also maintained strong financial discipline while continuing to invest in the long-term growth of the business and advance our product roadmap. The launch of ECoG Assistant marked an important first-of-its-kind step in extending the differentiated capabilities of the RNS System, building on NeuroPace's unique ability to continuously monitor and record each patient's intracranial EEG data, efficiently identify ECoGs of interest and support more individualized therapy, reinforcing a data advantage that other neuromodulation platforms cannot replicate.
"Looking ahead, we remain focused on sustaining momentum in our core business. Additionally, we look forward to continuing our engagement with the FDA regarding the path forward for our IGE PMA Panel Track supplement and remain on track with our clinical and regulatory timelines."
____________________
(1) Based on participants who received stimulation for 23 of 24 months
following implant and had completed 24-month follow-up with evaluable
data.
Discontinued Operations & Basis of Presentation
Following the expiration of the Company's distribution agreement with DIXI Medical and the related wind-down, the Company concluded in the second quarter of 2026 that the abandonment of its DIXI Medical product operations met the criteria for presentation as a discontinued operation under ASC 205-20. Unless otherwise noted, the results discussed in this release reflect continuing operations; prior-period amounts have been reclassified accordingly, with no effect on previously reported net loss, total assets, total liabilities, or total stockholders' equity. See the accompanying financial statements for the GAAP presentation of continuing and discontinued operations.
Second Quarter 2026 Financial Results
RNS System revenue totaled $22.5 million in the second quarter of 2026, representing growth of 21.3% compared to the second quarter of 2025. Total revenue in the second quarter of 2026 grew 17% to $22.8 million, compared with revenue of $19.5 million in the second quarter of 2025.
Non-GAAP gross margin for the second quarter of 2026 was 83.4%, compared with 84.0% in the second quarter of 2025. The slight year-over-year decline was driven by slightly higher material costs partially offset by favorable pricing. Total GAAP gross margin from continuing operations in the second quarter of 2026 was 82.8%.
Non-GAAP operating expenses in the second quarter of 2026 were $21.9 million, compared with $21.3 million in the second quarter of 2025. GAAP operating expenses in the second quarter of 2026 were $24.0 million.
Non-GAAP sales and marketing expense in the second quarter of 2026 was $11.5 million, compared with $10.7 million in the second quarter of 2025. The year-over-year increase was largely due to personnel-related expenses associated with ongoing scaling of commercial activities and other sales-related expenses.
Non-GAAP research and development expense in the second quarter of 2026 was $6.3 million, compared with $6.0 million in the second quarter of 2025. The year-over-year increase was primarily driven by an increase in product development-related expenses associated with a next-generation platform and AI-enabled tools.
Non-GAAP general and administrative expense in the second quarter of 2026 was $4.1 million compared with $4.6 million in the second quarter of 2025. The year-over-year decline was largely due to one-time expenses incurred in the prior period related to executive transition, partially offset by an increase in personnel-related expenses in the current period.
Non-GAAP loss from operations was ($2.8) million in the second quarter of 2026, compared with loss from operations of ($5.0) million in the second quarter of 2025. Non-GAAP net loss was ($3.9) million for the second quarter of 2026 compared with net loss of ($6.8) million in the second quarter of 2025. GAAP net loss in the second quarter of 2026 was ($6.2) million.
The Company's cash, cash equivalents, short-term investments and restricted cash balance as of June 30, 2026 was $51.9 million compared with $54.8 million at the end of the prior quarter. Long-term borrowings totaled $59.0 million as of June 30, 2026.
Full Year 2026 Financial Guidance
-- Increase total revenue guidance for full year 2026 to between $99.5
million and $101.5 million, compared with previously issued guidance of
$99 million to $101 million. The higher guidance reflects expected
service revenue of approximately $1 million, up from approximately
$500,000 previously, while the underlying RNS growth outlook of 21% to
23% remains unchanged. Consistent with previous guidance, this range
excludes any contribution from idiopathic generalized epilepsy indication
expansion.
-- Increase full year non-GAAP gross margin to between 82.0% and 83.0%, an
increase compared to 81.5% to 82.5% previously
-- Reiterate full year non-GAAP operating expenses to be between $90
million and $92 million, excluding approximately $10 million in
stock-based compensation, a non-cash expense
-- Increase Adjusted EBITDA to be between ($7.5) million and ($8.5)
million compared to previous guidance between ($8.5) million to ($9.5)
million
Non-GAAP Measure
To supplement NeuroPace's condensed financial statements presented in accordance with GAAP, the Company uses non-GAAP measures of certain components of financial performance. These non-GAAP measures include Adjusted EBITDA, non-GAAP gross margin, non-GAAP cost of goods sold, non-GAAP sales and marketing expense, non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss from operations. NeuroPace believes the presentation of its non-GAAP financial measures enhances the user's overall understanding of the Company's historical financial performance. The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies.
Webcast and Conference Call Information
NeuroPace will host a conference call to discuss the second quarter and full year 2026 financial results after market close on Tuesday, August 11, 2026, at 4:30 P.M. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at (click here). Individuals interested in participating in the call via telephone may access the call by dialing + 1 (833) 461-5787 and referencing Conference ID 246 660 202. The webcast will be archived on the Company's investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: Expectations regarding the Company's future revenue and growth based on a continued operations basis, excluding revenue from the DIXI Medical product operations; NeuroPace's expectations, forecasts and beliefs with respect to potential indication expansion for its RNS System and its software, technology and other product development efforts; increasing access to and adoption of RNS therapy as the standard of care in drug-resistant epilepsy; NeuroPace's continued execution on its long-term revenue growth strategy, including with respect to sustained revenue growth and long-term value creation. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: actual operating results may differ significantly from any guidance provided; uncertainties related to market acceptance and adoption of NeuroPace's RNS System and impacts to NeuroPace's revenue for 2026 and in the future; risks that NeuroPace's operating expenses could be higher than anticipated and that it could use its cash resources sooner than expected; risks that NeuroPace's gross margin may be lower than forecast; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace's RNS System, including risks related to the NAUTILUS submission and the forthcoming Submission Issue Request $(SIR)$ Q-Sub process; risks related to product development, including risks related to the development of AI-powered software, including NeuroPace AI(TM) and the next generation device platform; risks related to NeuroPace's reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 11, 2026, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
NeuroPace, Inc.
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
Three Months Ended June
30, Six Months Ended June 30,
-------------------------- ----------------------------
(in thousands, except
for share and per
share amounts) 2026 2025 2026 2025
---------- ---------- ---------- ----------
Revenue $ 22,826 $ 19,501 $ 44,829 $ 37,822
Cost of goods sold 3,920 3,288 7,912 6,478
---------- ---------- ---------- ----------
Gross profit 18,906 16,213 36,917 31,344
Operating expenses:
Sales and marketing 12,124 11,489 23,707 21,894
Research and
development 6,898 6,845 14,087 14,285
General and
administrative 5,027 6,068 9,871 10,114
---------- ---------- ---------- ----------
Total operating
expenses 24,049 24,402 47,665 46,293
---------- ---------- ---------- ----------
Loss from
continuing
operations (5,143) (8,189) (10,748) (14,949)
Interest income 523 718 1,088 1,511
Interest expense (1,539) (2,059) (3,060) (4,212)
Other income
(expense), net (41) (486) (206) (568)
---------- ---------- ---------- ----------
Net loss and
comprehensive
loss from
continuing
operations $ (6,200) $ (10,016) $ (12,926) $ (18,218)
---------- ---------- ---------- ----------
Net income from
discontinued
operations $ -- $ 1,365 $ 37 $ 2,978
---------- ---------- ---------- ----------
Net loss and
comprehensive
loss $ (6,200) $ (8,651) $ (12,889) $ (15,240)
========== ========== ========== ==========
Net loss per share
from continuing
operations
attributable to
common stockholders,
basic and diluted $ (0.18) $ (0.30) $ (0.38) $ (0.57)
========== ========== ========== ==========
Net income per share
from discontinued
operations
attributable to
common stockholders,
basic and diluted $ 0.00 $ 0.04 $ 0.00 $ 0.10
========== ========== ========== ==========
Net loss per share
attributable to
common stockholders,
basic and diluted $ (0.18) $ (0.26) $ (0.38) $ (0.47)
========== ========== ========== ==========
Weighted-average
shares used in
computing net loss
per share
attributable to
common stockholders,
basic and diluted 34,104,430 32,863,031 33,911,692 32,175,789
========== ========== ========== ==========
NeuroPace, Inc.
Condensed Balance Sheets
(unaudited)
June 30, December 31,
(in thousands, except for share and per
share amounts) 2026 2025
-------- ---------
Assets
Current assets:
Cash and cash equivalents $ 12,538 $ 21,692
Short-term investments 39,161 39,366
Accounts receivable 14,930 12,936
Inventory 18,111 14,862
Prepaid expenses and other current
assets 1,453 1,438
Current assets of discontinued
operations -- 3,779
-------- ---------
Total current assets 86,193 94,073
Property and equipment, net 1,243 1,125
Operating lease right-of-use asset 9,216 10,132
Restricted cash 241 122
Other assets 98 113
-------- ---------
Total assets $ 96,991 $ 105,565
======== =========
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 4,204 $ 1,776
Accrued liabilities 10,850 13,184
Operating lease liability 2,256 2,117
Deferred revenue 123 141
Current liabilities of discontinued
operations -- 596
-------- ---------
Total current liabilities 17,433 17,814
Long-term debt 59,014 58,884
Operating lease liability, net of current
portion 8,661 9,836
-------- ---------
Total liabilities 85,108 86,534
-------- ---------
Stockholders' equity:
Common stock, $0.001 par value 34 34
Additional paid-in capital 577,153 571,412
Accumulated deficit (565,304) (552,415)
-------- ---------
Total stockholders' equity 11,883 19,031
-------- ---------
Total liabilities and
stockholders' equity $ 96,991 $ 105,565
======== =========
NeuroPace, Inc.
Condensed Statements of Cash Flows
(unaudited)
Three Months Ended Six Months Ended June
June 30, 30,
------------------- ----------------------
(in thousands) 2026 2025 2026 2025
------ ------- ------- -------
Cash flows from
operating activities
Net loss $(6,200) $ (8,651) $(12,889) $(15,240)
Adjustments to
reconcile net loss to
net cash used in
operating activities:
Stock-based
compensation
expense 2,303 3,228 4,581 5,854
Depreciation 66 55 126 104
Amortization of
debt discount and
issuance costs 70 55 138 104
Non-cash interest
expense 80 177 157 390
Loss on debt
extinguishment -- 527 -- 527
Amortization of
right-of-use
asset 464 422 917 835
Unrealized loss
(gain) on
short-term
investments 41 (41) 206 41
Inventory
write-downs 68 49 144 93
Loss on disposal
of property and
equipment -- -- -- 2
Changes in
operating assets
and liabilities:
Accounts
receivable (141) 1,881 (249) (704)
Inventory (1,485) (2,815) (1,360) (3,058)
Prepaid
expenses and
other assets 63 521 (14) 671
Accounts
payable (212) 737 1,983 1,703
Accrued
liabilities 1,506 2,213 (2,489) (120)
Deferred
revenue (3) 17 (18) 141
Operating lease
liabilities (523) (461) (1,036) (911)
------ ------- ------- -------
Net cash
used in
operating
activities (3,903) (2,086) (9,803) (9,568)
------ ------- ------- -------
Cash flows from
investing activities
Acquisition of
property and
equipment (125) (168) (242) (205)
------ ------- ------- -------
Net cash
used in
investing
activities (125) (168) (242) (205)
------ ------- ------- -------
Cash flows from
financing activities
Proceeds from issuance
of common stock in
follow-on offering,
net of underwriting
discounts and
commissions -- (561) -- 69,704
Repurchase of common
stock from KCK Ltd. -- -- -- (49,546)
Proceeds from issuance
of common stock under
employee plans 1,377 766 1,387 1,151
Taxes withheld and
paid related to net
share settlement of
equity awards (51) (174) (227) (402)
Proceeds from
At-The-Market
offering, net of
sales commission -- -- -- 232
Proceeds from debt,
net of discounts and
issuance costs -- 58,568 -- 58,568
Payment of annual debt
fee (150) -- (150) --
Repayment of debt -- (60,507) -- (60,507)
------ ------- ------- -------
Net cash
provided
by (used
in)
financing
activities 1,176 (1,908) 1,010 19,200
------ ------- ------- -------
Net increase
(decrease) in cash
and cash equivalents (2,852) (4,162) (9,035) 9,427
Cash, cash equivalents
and restricted cash
at the Beginning of
Period 15,631 27,141 21,814 13,552
------ ------- ------- -------
Cash, cash equivalents
and restricted cash
at the End of Period $12,779 $ 22,979 $ 12,779 $ 22,979
====== ======= ======= =======
Reconciliation of
cash, cash equivalents
and restricted cash to
balance sheets:
Cash and cash
equivalents $12,538 $ 22,857 $ 12,538 $ 22,857
Restricted cash 241 122 241 122
------ ------- ------- -------
Cash, cash equivalents
and restricted cash
in balance sheets $12,779 $ 22,979 $ 12,779 $ 22,979
====== ======= ======= =======
NeuroPace, Inc.
Table 1. 2025 GAAP to Non-GAAP Reconciliations from Continuing Operations
(unaudited)
Three Months Ended Year Ended
------------------------------------------ -----------
March December
31, June 30, September 31, December
(in thousands) 2025 2025 30, 2025 2025 31, 2025
-------- --------- ----------- -------- -----------
RNS revenue $18,151 $ 18,564 $ 22,580 $22,374 $ 81,669
Service revenue 170 937 771 886 2,764
------ ------- ------ ------ -------
Revenue $18,321 $ 19,501 $ 23,351 $23,260 $ 84,433
====== ======= ====== ====== =======
GAAP cost of goods
sold $ 3,190 $ 3,288 $ 4,181 $ 4,405 $ 15,064
Stock-based
compensation 178 173 168 175 694
------ ------- ------ ------ -------
Non-GAAP cost
of goods sold $ 3,012 $ 3,115 $ 4,013 $ 4,230 $ 14,370
====== ======= ====== ====== =======
GAAP sales and
marketing expense $10,405 $ 11,489 $ 12,025 $10,713 $ 44,632
Stock-based
compensation 783 761 781 727 3,052
------ ------- ------ ------ -------
Non-GAAP sales
and marketing
expense $ 9,622 $ 10,728 $ 11,244 $ 9,986 $ 41,580
====== ======= ====== ====== =======
GAAP research and
development
expense $ 7,440 $ 6,845 $ 6,576 $ 7,027 $ 27,888
Stock-based
compensation 872 865 821 848 3,406
------ ------- ------ ------ -------
Non-GAAP
research and
development
expense $ 6,568 $ 5,980 $ 5,755 $ 6,179 $ 24,482
====== ======= ====== ====== =======
GAAP general and
administrative
expense $ 4,046 $ 6,068 $ 4,594 $ 4,382 $ 19,090
Stock-based
compensation 793 1,429 858 857 3,937
------ ------- ------ ------ -------
Non-GAAP
general and
administrative
expense $ 3,253 $ 4,639 $ 3,736 $ 3,525 $ 15,153
====== ======= ====== ====== =======
GAAP operating
expenses $21,891 $ 24,402 $ 23,195 $22,122 $ 91,610
Stock-based
compensation 2,448 3,055 2,460 2,432 10,395
------ ------- ------ ------ -------
Non-GAAP
operating
expenses $19,443 $ 21,347 $ 20,735 $19,690 $ 81,215
====== ======= ====== ====== =======
GAAP loss from
continuing
operations $(6,760) $ (8,189) $ (4,025) $(3,267) $(22,241)
Stock-based
compensation 2,626 3,228 2,628 2,607 11,089
------ ------- ------ ------ -------
Non-GAAP loss
from continuing
operations $(4,134) $ (4,961) $ (1,397) $ (660) $(11,152)
Depreciation 49 55 54 80 238
------ ------- ------ ------ -------
Adjusted
EBITDA from
continuing
operations
(Non-GAAP) $(4,085) $ (4,906) $ (1,343) $ (580) $(10,914)
====== ======= ====== ====== =======
GAAP loss from
continuing
operations $(6,760) $ (8,189) $ (4,025) $(3,267) $(22,241)
Interest and
other income
(expense), net (1,442) (1,827) (896) (962) (5,127)
------ ------- ------ ------ -------
GAAP net loss
from
continuing
operations $(8,202) $(10,016) $ (4,921) $(4,229) $(27,368)
Stock-based
compensation 2,626 3,228 2,628 2,607 11,089
------ ------- ------ ------ -------
Non-GAAP
net loss
from
continuing
operations $(5,576) $ (6,788) $ (2,293) $(1,622) $(16,279)
====== ======= ====== ====== =======
NeuroPace, Inc. Table 2. 2026 GAAP to Non-GAAP Reconciliations from
Continuing Operations (unaudited)
Six Months
Three Months Ended Ended
------------------------------ ---------------
(in thousands) March 31, 2026 June 30, 2026 June 30, 2026
-------------- -------------- ---------------
RNS revenue $ 21,689 $ 22,524 $ 44,213
Service revenue 314 302 616
--------- --------- --------
Revenue $ 22,003 $ 22,826 $ 44,829
========= ========= ========
GAAP cost of goods
sold $ 3,992 $ 3,920 $ 7,912
Stock-based
compensation 138 126 264
--------- --------- --------
Non-GAAP cost of
goods sold $ 3,854 $ 3,794 $ 7,648
========= ========= ========
GAAP sales and
marketing expense $ 11,583 $ 12,124 $ 23,707
Stock-based
compensation 595 650 1,245
--------- --------- --------
Non-GAAP sales
and marketing
expense $ 10,988 $ 11,474 $ 22,462
========= ========= ========
GAAP research and
development expense $ 7,189 $ 6,898 $ 14,087
Stock-based
compensation 713 624 1,337
--------- --------- --------
Non-GAAP research
and development
expense $ 6,476 $ 6,274 $ 12,750
========= ========= ========
GAAP general and
administrative
expense $ 4,844 $ 5,027 $ 9,871
Stock-based
compensation 832 903 1,735
--------- --------- --------
Non-GAAP general
and
administrative
expense $ 4,012 $ 4,124 $ 8,136
========= ========= ========
GAAP operating
expenses $ 23,616 $ 24,049 $ 47,665
Stock-based
compensation 2,140 2,177 4,317
--------- --------- --------
Non-GAAP
operating
expenses $ 21,476 $ 21,872 $ 43,348
========= ========= ========
GAAP loss from
continuing
operations $ (5,605) $ (5,143) $ (10,748)
Stock-based
compensation 2,278 2,303 4,581
--------- --------- --------
Non-GAAP loss
from continuing
operations $ (3,327) $ (2,840) $ (6,167)
Depreciation 60 66 126
--------- --------- --------
Adjusted
EBITDA from
continuing
operations
(Non-GAAP) $ (3,267) $ (2,774) $ (6,041)
========= ========= ========
GAAP loss from
continuing
operations $ (5,605) $ (5,143) $ (10,748)
Interest and other
income (expense),
net (1,121) (1,057) (2,178)
--------- --------- --------
GAAP net loss
from
continuing
operations $ (6,726) $ (6,200) $ (12,926)
Stock-based
compensation 2,278 2,303 4,581
--------- --------- --------
Non-GAAP
net loss
from
continuing
operations $ (4,448) $ (3,897) $ (8,345)
========= ========= ========
NeuroPace, Inc.
Table 3. GAAP to Non-GAAP Reconciliations
2026 Revised Guidance
(in thousands) 2026 Guidance
----------------------
RNS revenue $98,500 to $100,500
Service revenue 1,000
----------------------
Revenue $99,500 to $101,500
======================
GAAP gross margin 81.5% to 82.5%
Stock-based compensation 50 bps
----------------------
Non-GAAP gross margin 82.0% to 83.0%
======================
GAAP sales and marketing expense $49,000 to $51,000
Stock-based compensation 3,000
----------------------
Non-GAAP sales and marketing expense $46,000 to $48,000
======================
GAAP research and development expense $30,000
Stock-based compensation 3,000
----------------------
Non-GAAP research and development expense $27,000
======================
GAAP general and administrative expense $21,000
Stock-based compensation 4,000
----------------------
Non-GAAP general and administrative expense $17,000
======================
GAAP operating expenses $100,000 to $102,000
Stock-based compensation 10,000
----------------------
Non-GAAP operating expenses $90,000 to $92,000
======================
GAAP loss from operations ($18,500) to ($19,500)
Stock-based compensation (including gross margin) 10,500
----------------------
Non-GAAP loss from operations (8,000) to (9,000)
Depreciation 500
----------------------
Adjusted EBITDA (Non-GAAP) ($7,500) to ($8,500)
======================
View source version on businesswire.com: https://www.businesswire.com/news/home/20260811453255/en/
CONTACT: Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
investors@neuropace.com
Comments